ArticleThe Journal of pharmacology and experimental therapeutics2017
Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts.
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of pharmacology and experimental therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Aspirin-Derived Salicyl-CoA Drives Histone Lysine Salicylation Regulated by CBP and SIRT2.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Therapeutic Targets for Myocardial Fibrosis: A Comprehensive Review of Current and Emerging Approaches.Cardiovascular & hematological disorders drug targets · 2026Review
- Epigenetic regulation of cardiac physiology and pathophysiology: biological sex matters.The journal of cardiovascular aging · 2026Article
- Thermal shift engagement assay for Class IIA histone deacetylase inhibitor screening.Results in chemistry · 2025Article
- Myocardial transcriptomic and proteomic landscapes across the menopausal continuum in a murine model of chemically induced accelerated ovarian failure.Physiological genomics · 2025Article
- Progress and prospect of nanotechnology for cardiac fibrosis treatment.Interdisciplinary medicine · 2023Review
- Hippo-Yap signaling in cardiac and fibrotic remodeling.Current opinion in physiology · 2022Article
- Cardiac fibrosis.Cardiovascular research · 2021Review
- Application of Histone Deacetylase Inhibitors in Renal Interstitial Fibrosis.Kidney diseases (Basel, Switzerland) · 2020Review
- Protective transcriptional mechanisms in cardiomyocytes and cardiac fibroblasts.Journal of molecular and cellular cardiology · 2019Review
- HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice.Circulation. Arrhythmia and electrophysiology · 2019Article
- HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis.Therapeutic advances in chronic disease · 2019Review
- Pathological mechanisms and therapeutic outlooks for arthrofibrosis.Bone research · 2019Article
- Reactive Oxygen Species Drive Epigenetic Changes in Radiation-Induced Fibrosis.Oxidative medicine and cellular longevity · 2019Review
- Epigenetics in Cardiac Fibrosis: Emphasis on Inflammation and Fibroblast Activation.JACC. Basic to translational science · 2018Review
- Epigenetic signatures in cardiac fibrosis, special emphasis on DNA methylation and histone modification.Heart failure reviews · 2018Review
- Class I HDACs control a JIP1-dependent pathway for kinesin-microtubule binding in cardiomyocytes.Journal of molecular and cellular cardiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Katherine B SchuetzeDivision of Cardiology and Consortium for Fibrosis Research and Translation, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado (K.B.S., M.S.S., W.W.B., T.A.M.); Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical, Sciences, University of Colorado Denver, Aurora, Colorado (M.F.W.); Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts (F.F.W., E.B.H.); Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (Y.-M.K., A.J.A.); and Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (T.M.G., J.M.H.).
Matthew S StrattonDivision of Cardiology and Consortium for Fibrosis Research and Translation, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado (K.B.S., M.S.S., W.W.B., T.A.M.); Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical, Sciences, University of Colorado Denver, Aurora, Colorado (M.F.W.); Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts (F.F.W., E.B.H.); Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (Y.-M.K., A.J.A.); and Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (T.M.G., J.M.H.).
Weston W BlakesleeDivision of Cardiology and Consortium for Fibrosis Research and Translation, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado (K.B.S., M.S.S., W.W.B., T.A.M.); Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical, Sciences, University of Colorado Denver, Aurora, Colorado (M.F.W.); Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts (F.F.W., E.B.H.); Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (Y.-M.K., A.J.A.); and Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (T.M.G., J.M.H.).
Michael F WempeDivision of Cardiology and Consortium for Fibrosis Research and Translation, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado (K.B.S., M.S.S., W.W.B., T.A.M.); Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical, Sciences, University of Colorado Denver, Aurora, Colorado (M.F.W.); Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts (F.F.W., E.B.H.); Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (Y.-M.K., A.J.A.); and Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (T.M.G., J.M.H.).
Florence F WagnerDivision of Cardiology and Consortium for Fibrosis Research and Translation, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado (K.B.S., M.S.S., W.W.B., T.A.M.); Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical, Sciences, University of Colorado Denver, Aurora, Colorado (M.F.W.); Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts (F.F.W., E.B.H.); Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (Y.-M.K., A.J.A.); and Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (T.M.G., J.M.H.).
Edward B HolsonDivision of Cardiology and Consortium for Fibrosis Research and Translation, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado (K.B.S., M.S.S., W.W.B., T.A.M.); Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical, Sciences, University of Colorado Denver, Aurora, Colorado (M.F.W.); Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts (F.F.W., E.B.H.); Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (Y.-M.K., A.J.A.); and Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (T.M.G., J.M.H.).
Yin-Ming KuoDivision of Cardiology and Consortium for Fibrosis Research and Translation, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado (K.B.S., M.S.S., W.W.B., T.A.M.); Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical, Sciences, University of Colorado Denver, Aurora, Colorado (M.F.W.); Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts (F.F.W., E.B.H.); Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (Y.-M.K., A.J.A.); and Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (T.M.G., J.M.H.).
Andrew J AndrewsDivision of Cardiology and Consortium for Fibrosis Research and Translation, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado (K.B.S., M.S.S., W.W.B., T.A.M.); Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical, Sciences, University of Colorado Denver, Aurora, Colorado (M.F.W.); Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts (F.F.W., E.B.H.); Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (Y.-M.K., A.J.A.); and Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (T.M.G., J.M.H.).
Tonya M GilbertDivision of Cardiology and Consortium for Fibrosis Research and Translation, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado (K.B.S., M.S.S., W.W.B., T.A.M.); Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical, Sciences, University of Colorado Denver, Aurora, Colorado (M.F.W.); Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts (F.F.W., E.B.H.); Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (Y.-M.K., A.J.A.); and Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (T.M.G., J.M.H.).
Jacob M HookerDivision of Cardiology and Consortium for Fibrosis Research and Translation, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado (K.B.S., M.S.S., W.W.B., T.A.M.); Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical, Sciences, University of Colorado Denver, Aurora, Colorado (M.F.W.); Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts (F.F.W., E.B.H.); Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (Y.-M.K., A.J.A.); and Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (T.M.G., J.M.H.).
Timothy A McKinseyDivision of Cardiology and Consortium for Fibrosis Research and Translation, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado (K.B.S., M.S.S., W.W.B., T.A.M.); Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical, Sciences, University of Colorado Denver, Aurora, Colorado (M.F.W.); Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts (F.F.W., E.B.H.); Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (Y.-M.K., A.J.A.); and Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (T.M.G., J.M.H.) timothy.mckinsey@ucdenver.edu.
University of Colorado Anschutz Medical Campus · USHarvard University · USBroad Institute · USFox Chase Cancer Center · USMassachusetts Institute of Technology · USUniversity of Colorado Denver · USUniversity of Montana · US
Funding
Regulation of Chromatin Signaling in Heart Failure by the BRD4 Bromodomain Protein.R01HL127240 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI MCKINSEY, TIMOTHY, SRIVASTAVA, DEEPAK · 2015 to 2022
$6.4MPOSTGRADUATE TRAINING IN CARDIOVASCULAR RESEARCHT32HL007822 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI BUTTRICK, PETER N., LEINWAND, LESLIE ANNE · 1996 to 2023
$6.2MPREDOCTORAL TRAINING PROGRAM IN PHARMACOLOGYT32GM007635 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI DELL'ACQUA, MARK L · 1985 to 2023
$6.1MThe Role of Histone Chaperones in Histone Acetylation and Nucleosome DynamicsR01GM102503 · NIGMS · UNIVERSITY OF NORTH CAROLINA WILMINGTON · PI ANDREWS, ANDREW JOSEPH · 2014 to 2023
$3.9MRegulation of Cardiac Signaling by Class I Histone DeacetylasesR01HL116848 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI MCKINSEY, TIMOTHY · 2013 to 2021
$3.1MIsoform-Selective HDAC Inhibitors for Age-Associated Diastolic DysfunctionR21AG043822 · NIA · UNIVERSITY OF COLORADO DENVER · PI MCKINSEY, TIMOTHY · 2012 to 2013
$414kRole of BET proteins in cardiac remodelingF32HL126354 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI STRATTON, MATTHEW · 2015 to 2015
$54kNHLBI NIH HHS F32 HL126354NHLBI NIH HHS R01 HL116848NHLBI NIH HHS R01 HL127240NHLBI NIH HHS T32 HL007822NIA NIH HHS R21 AG043822NIGMS NIH HHS R01 GM102503NIGMS NIH HHS T32 GM007635
Abstract
Inhibitors of zinc-dependent histone deacetylases (HDACs) profoundly affect cellular function by altering gene expression via changes in nucleosomal histone tail acetylation. Historically, investigators have employed pan-HDAC inhibitors, such as the hydroxamate trichostatin A (TSA), which simultaneously targets members of each of the three zinc-dependent HDAC classes (classes I, II, and IV). More recently, class- and isoform-selective HDAC inhibitors have been developed, providing invaluable chemical biology probes for dissecting the roles of distinct HDACs in the control of various physiologic and pathophysiological processes. For example, the benzamide class I HDAC-selective inhibitor, MGCD0103 [
Indexed as
AnimalsAnimals, NewbornCells, CulturedFibroblastsHistone Deacetylase 1Histone Deacetylase InhibitorsMiceMice, Inbred C57BLMyocytes, CardiacRatsRats, Sprague-DawleyHistone Deacetylase 1Histone Deacetylase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.